Continuing Allston Troubles Mean Another Brief Shutdown, Delay For Lumizyme Approval
An FDA "complete response" letter in relation to Genzyme's sBLA for Lumizyme says plant problems must be resolved before approval.
An FDA "complete response" letter in relation to Genzyme's sBLA for Lumizyme says plant problems must be resolved before approval.